Momenta Pharmaceuticals is a biotechnology company based in Cambridge, MA focused on the development of complex generics, follow-on biologics and novel drugs. In July 2010, the company's lead product (developed in collaboration with Sandoz) was approved as the first generic version of Lovenox® (enoxaparin sodium injection). The company’s development pipeline includes a generic version of Copaxone® (glatiramer acetate), also in collaboration with Sandoz, follow-on biologics in collaboration with Baxter, and necuparanib (formerly M402), a novel oncology drug candidate currently undergoing testing in early phase human clinical trials. Necuparanib has received Orphan Drug Designation from the U.S. Food and Drug Administration (FDA) for the treatment of pancreatic cancer.
View all » Recent Releases
View all »Events & Presentations
Sep 26, 2014 at 3:00 PM ET
Last Revised 6/12/2012